SWKHLHIGH SIGNALFINANCIAL10-K

SWKHL underwent a dramatic financial transformation with a massive cash increase but swing from $13.5M profit to $2.5M loss, alongside pending mergers and apparent business restructuring.

The company appears to be in the midst of significant corporate activity, evidenced by pending mergers mentioned in new risk language and a fundamental shift in financial performance. The dramatic cash increase suggests either asset sales, financing activities, or merger-related transactions, while the profit-to-loss swing indicates major operational changes that investors need to understand.

Comparing 2026-03-20 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

SWKHL's financials show contradictory signals with cash surging 621% to $42.8M and operating income growing 75% to $20.3M, yet the company swung from $13.5M net income to a $2.5M loss due to interest expense spiking 444% to $1.8M. The massive cash build alongside reduced share buybacks and mention of pending mergers suggests the company is either preparing for or in the midst of significant M&A activity. The combination of strong operating performance but negative net income due to financing costs creates an unusual financial profile that demands immediate investor attention.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+621.5%
$5.9M$42.8M

Cash position surged 621.5% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
+443.8%
$340K$1.8M

Interest expense surged 443.8% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
+271%
$138K$512K

Capital expenditure jumped 271% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
+131%
$20.3M$46.8M

Current assets grew 131% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
-118.8%
$13.5M-$2.5M

Net income declined 118.8% — review whether driven by operations, interest costs, or non-recurring items.

Accounts Receivable
Balance Sheet
+99.4%
$528K$1.1M

Receivables surged 99.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Income
P&L
+75%
$11.6M$20.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Share Buybacks
Cash Flow
-49%
$6.0M$3.1M

Buyback activity reduced 49% — capital being redeployed elsewhere or cash conservation underway.

Provision for Credit Losses
P&L
-45.2%
$3.5M$1.9M

Provisions reduced 45.2% — improving credit quality or reserve release boosting reported earnings.

R&D Expense
P&L
-29.6%
$2.2M$1.6M

R&D spending cut 29.6% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-20
PRIOR — 2025-03-20
ADDED
Property and equipment, net consisted of the following (in thousands): December 31, 2025 December 31, 2024 Production equipment and other $ $ 4,079 Furniture and fixtures 139 198 Leasehold improvements 13 3,645 Capitalized software 16 192 Total 168 8,114 Less accumulated depreciation and amortization (120) (2,676) Property and equipment, net $ 48 $ 5,438 Depreciation and amortization expense on property and equipment was $0.9 million and $0.8 million for the year ended December 31, 2025 and 2024, respectively.
On March 16, 2026, the Registrant had outstanding approximat ely 12,095,979 shares of C ommon Stock, $0.001 par value per share.
We generally do not control our partner companies, and our partner companies may make decisions with which we don t agree or that don t serve our business or financial interests.
Public health epidemics, pandemics or outbreaks could adversely affect our and our partner companies businesses.
The announcement and pendency of the Mergers could adversely affect our businesses, financial results and operations.
+7 more — sign up free →
REMOVED
On March 13, 2025, the Registrant had outstanding approximat ely 12,252,816 shares of C ommon Stock, $0.001 par value per share.
We also own trademarks in several foreign countries and may pursue registration of other trademarks.
Our operations comprise two reportable segments: Finance Receivables and Pharmaceutical Development.
We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources.
In addition, through our wholly-owned subsidiary, SWK Advisors LLC, we are able to provide non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →